143 related articles for article (PubMed ID: 36502356)
1. Role of colony-stimulating factor 1 in the neoplastic process of tenosynovial giant cell tumor.
Tap WD; Healey JH
Tumour Biol; 2022; 44(1):239-248. PubMed ID: 36502356
[TBL] [Abstract][Full Text] [Related]
2. Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
Mastboom MJL; Hoek DM; Bovée JVMG; van de Sande MAJ; Szuhai K
Histopathology; 2019 Jan; 74(2):332-340. PubMed ID: 30152874
[TBL] [Abstract][Full Text] [Related]
3. Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches.
Spierenburg G; van der Heijden L; van Langevelde K; Szuhai K; Bovée JVGM; van de Sande MAJ; Gelderblom H
Expert Opin Ther Targets; 2022 Apr; 26(4):333-345. PubMed ID: 35443852
[TBL] [Abstract][Full Text] [Related]
4. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
Baldi GG; Gronchi A; Stacchiotti S
Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
[TBL] [Abstract][Full Text] [Related]
5. Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors.
van IJzendoorn DGP; Matusiak M; Charville GW; Spierenburg G; Varma S; Colburg DRC; van de Sande MAJ; van Langevelde K; Mohler DG; Ganjoo KN; Bui NQ; Avedian RS; Bovée JVMG; Steffner R; West RB; van de Rijn M
Clin Cancer Res; 2022 Nov; 28(22):4934-4946. PubMed ID: 36007098
[TBL] [Abstract][Full Text] [Related]
6. Detection of CSF1 rearrangements deleting the 3' UTR in tenosynovial giant cell tumors.
Ho J; Peters T; Dickson BC; Swanson D; Fernandez A; Frova-Seguin A; Valentin MA; Schramm U; Sultan M; Nielsen TO; Demicco EG
Genes Chromosomes Cancer; 2020 Feb; 59(2):96-105. PubMed ID: 31469468
[TBL] [Abstract][Full Text] [Related]
7. Establishment and characterization of a novel cell line, NCC-TGCT1-C1, derived from a patient with tenosynovial giant cell tumor.
Noguchi R; Yoshimatsu Y; Ono T; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
Hum Cell; 2021 Jan; 34(1):254-259. PubMed ID: 32886306
[TBL] [Abstract][Full Text] [Related]
8. Multimodal management of tenosynovial giant cell tumors (TGCT) in the landscape of new druggable targets.
van der Heijden L; Spierenburg G; Kendal JK; Bernthal NM; van de Sande MAJ
J Surg Oncol; 2023 Sep; 128(3):478-488. PubMed ID: 37537982
[TBL] [Abstract][Full Text] [Related]
9. Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis.
Thongchot S; Duangkaew S; Yotchai W; Maungsomboon S; Phimolsarnti R; Asavamongkolkul A; Thuwajit P; Thuwajit C; Chandhanayingyong C
Hum Cell; 2023 Jan; 36(1):456-467. PubMed ID: 36456782
[TBL] [Abstract][Full Text] [Related]
10. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
[TBL] [Abstract][Full Text] [Related]
11. Intramuscular Tenosynovial Giant Cell Tumor Harboring a Novel
Mejbel H; Siegal GP; Wei S
Int J Surg Pathol; 2022 May; 30(3):335-338. PubMed ID: 34657489
[TBL] [Abstract][Full Text] [Related]
12. Neoplastic synovial lining cells that coexpress podoplanin and CD90 overproduce CSF-1, driving tenosynovial giant cell tumor.
Chandler AC; Yakoub M; Fujiwara T; Donlin LT; Purdue PE; Healey JH
J Orthop Res; 2022 Aug; 40(8):1918-1925. PubMed ID: 34855235
[TBL] [Abstract][Full Text] [Related]
13. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.
Brahmi M; Vinceneux A; Cassier PA
Curr Treat Options Oncol; 2016 Feb; 17(2):10. PubMed ID: 26820289
[TBL] [Abstract][Full Text] [Related]
14. Treatment updates on tenosynovial giant cell tumor.
Palmerini E; Staals EL
Curr Opin Oncol; 2022 Jul; 34(4):322-327. PubMed ID: 35837703
[TBL] [Abstract][Full Text] [Related]
15. Tenosynovial giant cell tumor.
Kager M; Kager R; Fałek P; Fałek A; Szczypiór G; Niemunis-Sawicka J; Rzepecka-Wejs L; Starosławska E; Burdan F
Folia Med Cracov; 2022; 62(2):93-107. PubMed ID: 36256897
[TBL] [Abstract][Full Text] [Related]
16. RNAscope CSF1 chromogenic in situ hybridization: a potentially useful tool in the differential diagnosis of tenosynovial giant cell tumors.
Thangaiah JJ; Koepplin JW; Folpe AL
Hum Pathol; 2021 Sep; 115():1-9. PubMed ID: 34058245
[TBL] [Abstract][Full Text] [Related]
17. A novel colony-stimulating factor 1 (CSF1) translocation involving human endogenous retroviral element in a tenosynovial giant cell tumor.
Lipplaa A; Meijer D; van de Sande MAJ; Gelderblom H; Bovée JVMG; Mei H; Szuhai K
Genes Chromosomes Cancer; 2023 Apr; 62(4):223-230. PubMed ID: 36504457
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.
Gelhorn HL; Tong S; McQuarrie K; Vernon C; Hanlon J; Maclaine G; Lenderking W; Ye X; Speck RM; Lackman RD; Bukata SV; Healey JH; Keedy VL; Anthony SP; Wagner AJ; Von Hoff DD; Singh AS; Becerra CR; Hsu HH; Lin PS; Tap WD
Clin Ther; 2016 Apr; 38(4):778-93. PubMed ID: 27041409
[TBL] [Abstract][Full Text] [Related]
19. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
Palmerini E; Longhi A; Donati DM; Staals EL
Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819
[TBL] [Abstract][Full Text] [Related]
20. Updates on the Treatment of Tenosynovial Giant Cell Tumor.
Chan AS; Katiyar V; Dy P; Singh V
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):307-315. PubMed ID: 37363972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
